Your request to link to rcsb for Bile acid receptor

• 1OSH: a chemical, genetic, and structural analysis of the nuclear bile acid receptor fxr (10.1016/S1097-2765(03)00104-7 )
• 1OSV: structural basis for bile acid binding and activation of the nuclear receptor fxr (10.1016/S1097-2765(03)00112-6 )
• 1OT7: structural basis for 3-deoxy-cdca binding and activation of fxr (10.1016/S1097-2765(03)00112-6 )
• 3BEJ: structure of human fxr in complex with mfa-1 and co-activator peptide (10.1073/PNAS.0710981105 )
• 3DCT: fxr with src1 and gw4064 (10.1016/J.BMCL.2008.06.073 )
• 3DCU: fxr with src1 and gsk8062 (10.1016/J.BMCL.2008.06.073 )
• 3FLI: discovery of xl335, a highly potent, selective and orally- active agonist of the farnesoid x receptor (fxr) (10.1021/JM8014124 )
• 3FXV: identification of an n-oxide pyridine gw4064 analogue as a potent fxr agonist (10.1016/J.BMCL.2009.03.008 )
• 3GD2: isoxazole ligand bound to farnesoid x receptor (fxr) (10.1016/J.BMCL.2009.04.047 )
• 3HC5: fxr with src1 and gsk826 (10.1016/J.BMCL.2009.06.062 )
• 3HC6: fxr with src1 and gsk088 (10.1016/J.BMCL.2009.06.062 )
• 3L1B: complex structure of fxr ligand-binding domain with a tetrahydroazepinoindole compound (10.1021/JM901650U )
• 3OKH: crystal structure of human fxr in complex with 2-(4-chlorophenyl)-1- [(1s)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1h-benzimidazole- 6-carboxylic acid (10.1016/J.BMCL.2010.11.039 )
• 3OKI: crystal structure of human fxr in complex with (2s)-2-[2-(4- chlorophenyl)-1h-benzimidazol-1-yl]-n,2-dicyclohexylethanamide (10.1016/J.BMCL.2010.11.039 )
• 3OLF: crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4- chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2- cyclohexylacetyl}amino)-3-methylbenzoic acid (10.1016/J.BMCL.2010.12.123 )
• 3OMK: crystal structure of human fxr in complex with (2s)-2-[2-(4- chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexyl-n-(2- methylphenyl)ethanamide (10.1016/J.BMCL.2010.12.123 )
• 3OMM: crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4- chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2- cyclohexylacetyl}amino)-3-fluorobenzoic acid (10.1016/J.BMCL.2010.12.123 )
• 3OOF: crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4- chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2- cyclohexylacetyl}amino)benzoic acid (10.1016/J.BMCL.2010.12.123 )
• 3OOK: crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4- chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2- cyclohexylacetyl}amino)-3,5-difluorobenzoic acid (10.1016/J.BMCL.2010.12.123 )
• 3P88: fxr bound to isoquinolinecarboxylic acid (10.1016/J.BMCL.2010.12.089 )
• 3P89: fxr bound to a quinolinecarboxylic acid (10.1016/J.BMCL.2010.12.089 )
• 3RUT: fxr with src1 and gsk359 (10.1016/J.BMCL.2011.08.034 )
• 3RUU: fxr with src1 and gsk237 (10.1016/J.BMCL.2011.08.034 )
• 3RVF: fxr with src1 and gsk2034 (10.1016/J.BMCL.2011.08.034 )
• 4OIV: structural basis for small molecule ndb as a selective antagonist of fxr (10.1074/JBC.M114.630475 )
• 4QE6: fxr with cdca and ncoa-2 peptide
• 4QE8: fxr with dm175 and ncoa-2 peptide
• 4WVD: identification of a novel fxr ligand that regulates metabolism (10.1038/NCOMMS2924 )
• 5IAW: novel natural fxr modulator with a unique binding mode (10.1002/CBIC.201700059 )
• 5ICK: a unique binding model of fxr lbd with feroline (10.1002/CBIC.201700059 )
• 5Q0I: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0J: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0K: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0L: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0M: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0N: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0O: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0P: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0Q: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0R: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0S: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0T: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0U: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0V: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0W: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0X: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0Y: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q0Z: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q10: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q11: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q12: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q13: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q14: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q15: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q16: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q17: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q18: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q19: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1A: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1B: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1C: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1D: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1E: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1F: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1G: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1H: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5Q1I: ligand binding to farnesoid-x-receptor (10.1007/S10822-017-0088-4 )
• 5WZX: structural basis for a pentacyclic oleanane-type triterpenoid as a ligand of fxr (10.1124/MOL.117.109900 )
• 5Y1J: crystal structure of human fxr in complex with a functional drug ligand
• 5Y44: a novel moderator xd4 for bile acid receptor
• 5Y49: a moderator xd22 binding to bile acid receptor
• 5YXB: a ligand binding to fxr
• 5YXD: a ligand f binding to fxr
• 5YXJ: fxr ligand binding domain
• 5YXL: a ligand m binding to fxr
• 5Z12: a structure of fxr/rxr (10.1074/JBC.RA118.004188 )
• 6A5W: fxr-lbd with hnc143 and src1 (10.1074/JBC.RA118.004652 )
• 6A5X: fxr-lbd with hnc180 and src1 (10.1074/JBC.RA118.004652 )
• 6A5Y: crystal structure of human fxr/rxr-lbd heterodimer bound to hnc143 and 9cra and src1 (10.1074/JBC.RA118.004652 )
• 6A5Z: crystal structure of human fxr/rxr-lbd heterodimer bound to hnc180 and 9cra and src1 (10.1074/JBC.RA118.004652 )
• 6A60: crystal structure of human fxr/rxr-lbd heterodimer bound to gw4064 and 9cra and src1 (10.1074/JBC.RA118.004652 )
• 6HL0: crystal structure of farnesoid x receptor (fxr) with bound ncoa-2 peptide (10.1038/S41467-019-10853-2 )
• 6HL1: crystal structure of farnesoid x receptor (fxr) with bound ncoa-2 peptide and cdca (10.1038/S41467-019-10853-2 )
• 6ITM: crystal structure of fxr in complex with agonist xj034 (10.1021/ACS.JCIM.9B01030 )
• 7D42: structural basis of tropifexor as a potent and selective agonist for farnesoid x receptor (10.1016/J.BBRC.2020.10.039 )
• 7TRB: crystal structure of farnesoid x-activated receptor complexed with compound-32 aka (1s,3s)-n-({4-[5-(2-fluoropr opan-2-yl)-1,2,4- oxadiazol-3-yl]bicyclo[2.2.2]octan-1-yl}m ethyl)-3-hydroxy-n-[4'-(2- hydroxypropan-2-yl)-[1,1'-biphen yl]-3-yl]-3-(trifluoromethyl) cyclobutane-1-carboxamide (10.1021/ACS.JMEDCHEM.2C00165 )
• 7VUE: structural insight of the molecular mechanism of cilofexor bound to fxr (10.1016/J.BBRC.2022.01.069 )